Positive Larotrectinib Data for TRK Fusion Cancer Presented at ESMO
September 29th 2019At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.